TAK-751S

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameTAK-751S
Drug Alias NameChromosorb (hemolytic uremic syndrome)Synsorb PkTAK-7515TAK-751STAK-157F
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsAtypical Hemolytic Uremic SyndromeHemolytic-Uremic SyndromeKidney Diseases +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSynsorb Biotech
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsAtypical Hemolytic Uremic SyndromeHemolytic-Uremic SyndromeKidney Diseases +[4

Other Information

ATC CodeN/A
Related LinksN/A